WGU D116 Advanced
Pharmacology: Comprehensive OA
& Exam Preparation Guide
(2026/2027) – 300 Verified
Questions with Detailed Rationales
PHARMACOKINETICS & PHARMACODYNAMICS
Q1: The first-pass effect refers to:
• A) Rapid intravenous administration
• B) Drug metabolism in the liver before reaching systemic
circulation (primarily for oral drugs)
• C) Drug excretion by the kidneys
• D) Drug binding to plasma proteins
Answer: B
Rationale: The first-pass effect reduces the bioavailability of orally
administered drugs. Drugs absorbed from the gastrointestinal tract pass
through the portal circulation to the liver, where they undergo
metabolism before reaching systemic circulation. This is why some drugs
require higher oral doses compared to IV administration.
Q2: Which route of administration bypasses the first-pass effect?
• A) Oral
• B) Sublingual
• C) Rectal
• D) Enteral
,Answer: B
Rationale: Sublingual administration allows direct absorption into
systemic circulation through the oral mucosa, bypassing portal
circulation and hepatic first-pass metabolism. This provides rapid onset
and is why nitroglycerin is given sublingually.
Q3: The half-life of a drug is:
• A) The time to reach maximum concentration
• B) The time for plasma concentration to decrease by 50%
• C) The time between doses
• D) The time to eliminate the drug completely
Answer: B
Rationale: Half-life (t½) determines dosing interval and steady-state
concentration. It is the time required for the plasma concentration of a
drug to decrease by 50%. Steady-state concentration is reached after
approximately 4-5 half-lives.
Q4: Which factor most significantly affects the distribution of a
highly protein-bound drug?
• A) Hepatic blood flow
• B) Serum albumin levels
• C) Renal function
• D) Gastric pH
Answer: B
Rationale: Serum albumin levels directly affect distribution of highly
protein-bound drugs. Decreased albumin (malnutrition, liver disease,
nephrotic syndrome) increases free drug concentration, potentially
leading to toxicity. Only unbound (free) drug is pharmacologically active.
,Q5: The therapeutic index (TI) is best defined as:
• A) The difference between maximum and minimum dose
• B) The ratio between the toxic dose (TD50) and effective dose
(ED50)
• C) The ratio between the effective dose and lethal dose
• D) The time between doses and steady state
Answer: B
Rationale: Therapeutic index = TD50/ED50. A narrow therapeutic index
means the margin between therapeutic and toxic levels is small,
requiring close monitoring. Examples include digoxin, warfarin,
phenytoin, and lithium.
Q6: A competitive antagonist:
• A) Irreversibly inhibits the receptor
• B) Binds permanently to receptors
• C) Competes with the agonist at the same binding site
• D) Enhances the agonist effect
Answer: C
Rationale: Competitive antagonists bind reversibly to receptors and can
be displaced by increasing agonist concentration. This contrasts with
non-competitive antagonists, which bind irreversibly or at allosteric sites
and cannot be overcome. Examples include beta-blockers and naloxone.
Q7: Which CYP450 enzyme is responsible for metabolizing the
largest number of drugs?
• A) CYP1A
• B) CYP2D
, • C) CYP3A
• D) CYP2C
Answer: C
Rationale: CYP3A4 is the most abundant CYP450 enzyme, metabolizing
approximately 50% of all drugs. It is a frequent site of clinically
significant drug interactions.
Q8: A CYP450 inhibitor would:
• A) Increase metabolism of other drugs
• B) Decrease metabolism of other drugs
• C) Have no effect on other drugs
• D) Increase drug excretion
Answer: B
Rationale: A CYP450 inhibitor reduces enzyme activity, decreasing
metabolism of other drugs that rely on that enzyme. This leads to
increased drug levels and potential toxicity. Examples include
ketoconazole, erythromycin, and ciprofloxacin.
Q9: A patient taking warfarin (CYP2C9 substrate) starts taking
amiodarone (CYP2C9 inhibitor). The expected effect is:
• A) Decreased warfarin levels
• B) Increased warfarin levels (risk of bleeding)
• C) No change in warfarin levels
• D) Increased warfarin metabolism
Answer: B
Rationale: Amiodarone inhibits CYP2C9, decreasing warfarin
metabolism. This leads to elevated INR and increased bleeding risk.
Warfarin requires close monitoring with any CYP2C9 inhibitor.
Pharmacology: Comprehensive OA
& Exam Preparation Guide
(2026/2027) – 300 Verified
Questions with Detailed Rationales
PHARMACOKINETICS & PHARMACODYNAMICS
Q1: The first-pass effect refers to:
• A) Rapid intravenous administration
• B) Drug metabolism in the liver before reaching systemic
circulation (primarily for oral drugs)
• C) Drug excretion by the kidneys
• D) Drug binding to plasma proteins
Answer: B
Rationale: The first-pass effect reduces the bioavailability of orally
administered drugs. Drugs absorbed from the gastrointestinal tract pass
through the portal circulation to the liver, where they undergo
metabolism before reaching systemic circulation. This is why some drugs
require higher oral doses compared to IV administration.
Q2: Which route of administration bypasses the first-pass effect?
• A) Oral
• B) Sublingual
• C) Rectal
• D) Enteral
,Answer: B
Rationale: Sublingual administration allows direct absorption into
systemic circulation through the oral mucosa, bypassing portal
circulation and hepatic first-pass metabolism. This provides rapid onset
and is why nitroglycerin is given sublingually.
Q3: The half-life of a drug is:
• A) The time to reach maximum concentration
• B) The time for plasma concentration to decrease by 50%
• C) The time between doses
• D) The time to eliminate the drug completely
Answer: B
Rationale: Half-life (t½) determines dosing interval and steady-state
concentration. It is the time required for the plasma concentration of a
drug to decrease by 50%. Steady-state concentration is reached after
approximately 4-5 half-lives.
Q4: Which factor most significantly affects the distribution of a
highly protein-bound drug?
• A) Hepatic blood flow
• B) Serum albumin levels
• C) Renal function
• D) Gastric pH
Answer: B
Rationale: Serum albumin levels directly affect distribution of highly
protein-bound drugs. Decreased albumin (malnutrition, liver disease,
nephrotic syndrome) increases free drug concentration, potentially
leading to toxicity. Only unbound (free) drug is pharmacologically active.
,Q5: The therapeutic index (TI) is best defined as:
• A) The difference between maximum and minimum dose
• B) The ratio between the toxic dose (TD50) and effective dose
(ED50)
• C) The ratio between the effective dose and lethal dose
• D) The time between doses and steady state
Answer: B
Rationale: Therapeutic index = TD50/ED50. A narrow therapeutic index
means the margin between therapeutic and toxic levels is small,
requiring close monitoring. Examples include digoxin, warfarin,
phenytoin, and lithium.
Q6: A competitive antagonist:
• A) Irreversibly inhibits the receptor
• B) Binds permanently to receptors
• C) Competes with the agonist at the same binding site
• D) Enhances the agonist effect
Answer: C
Rationale: Competitive antagonists bind reversibly to receptors and can
be displaced by increasing agonist concentration. This contrasts with
non-competitive antagonists, which bind irreversibly or at allosteric sites
and cannot be overcome. Examples include beta-blockers and naloxone.
Q7: Which CYP450 enzyme is responsible for metabolizing the
largest number of drugs?
• A) CYP1A
• B) CYP2D
, • C) CYP3A
• D) CYP2C
Answer: C
Rationale: CYP3A4 is the most abundant CYP450 enzyme, metabolizing
approximately 50% of all drugs. It is a frequent site of clinically
significant drug interactions.
Q8: A CYP450 inhibitor would:
• A) Increase metabolism of other drugs
• B) Decrease metabolism of other drugs
• C) Have no effect on other drugs
• D) Increase drug excretion
Answer: B
Rationale: A CYP450 inhibitor reduces enzyme activity, decreasing
metabolism of other drugs that rely on that enzyme. This leads to
increased drug levels and potential toxicity. Examples include
ketoconazole, erythromycin, and ciprofloxacin.
Q9: A patient taking warfarin (CYP2C9 substrate) starts taking
amiodarone (CYP2C9 inhibitor). The expected effect is:
• A) Decreased warfarin levels
• B) Increased warfarin levels (risk of bleeding)
• C) No change in warfarin levels
• D) Increased warfarin metabolism
Answer: B
Rationale: Amiodarone inhibits CYP2C9, decreasing warfarin
metabolism. This leads to elevated INR and increased bleeding risk.
Warfarin requires close monitoring with any CYP2C9 inhibitor.
